## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

- (Canceled)
- (Currently amended) <u>A compound The compound of claim 1</u>, having the structure of Formula I:

$$HO \longrightarrow (CH_2)_n$$

wherein R is lower alkyl or halo and n is 0-5, or a pharmaceutically acceptable salt thereof.

 (Currently amended) <u>A compound The compound of claim 1,</u> having the structure of Formula II:

wherein R is lower alkyl, or a pharmaceutically acceptable salt thereof.

 (Currently amended) <u>A compound</u> The compound of claim 1, having the structure of Formula III:

wherein R is lower alkyl, or a pharmaceutically acceptable salt thereof.

 (Currently amended) <u>A compound The compound of claim 1</u>, having the structure of Formula IV:

wherein R<sup>a</sup> and R<sup>b</sup> are each independently hydrogen, lower alkyl or halo, n is 1-5, and V is (CH<sub>2</sub>)<sub>to</sub> CONH, or CONHCH<sub>2</sub>, or a pharmaceutically acceptable salt thereof.

- (Currently amended) A pharmaceutical composition comprising a compound of any one of claims 2-5 elaim-1 and a pharmaceutically acceptable carrier.
- (Currently amended) A method of treating a hyperproliferative disease or cancer in an animal, comprising administering to said animal a therapeutically effective amount of a compound of any one of claims 2-5 elaim 1.

- (Original) The method of claim 7, further comprising administering an inducer of apoptosis.
- (Original) The method of claim 8, wherein said inducer of apoptosis is a chemotherapeutic agent.
- (Original) The method of claim 9, wherein said chemotherapeutic agent is embelin.
- (Original) The method of claim 8, wherein said inducer of apoptosis is radiation.
- (Currently amended) The method of claim 8, wherein said compound of elaim 1 is administered prior to said inducer of apoptosis.
- (Currently amended) The method of claim 8, wherein said compound of elaim 1 is administered concurrently with said inducer of apoptosis.
- (Currently amended) The method of claim 8, wherein said compound of elaim 1 is administered after said inducer of apoptosis.
- (Currently amended) A method of inducing apoptosis in a cell comprising contacting said cell with a compound of any one of claims 2-5 elaim 1.

- (Currently amended) A method of rendering a cell sensitive to an inducer
  of apoptosis comprising contacting said cell with a compound of <u>any one of claims 2-5</u>
  elaim 1.
- (Original) The method of claim 16, further comprising contacting said cell with an inducer of apoptosis.

## 18-19. (Canceled)

- (Currently amended) A kit comprising a compound of any one of claims
   2.5 claim 1 and instructions for administering said compound to an animal.
- (Original) The kit of claim 20, further comprising an inducer of apoptosis.
- (Original) The kit of claim 21, wherein said inducer of apoptosis is a chemotherapeutic agent.
- (Original) The kit of claim 22, wherein said chemotherapeutic agent is embelin.

- 24. (Original) The kit of claim 20, wherein said instructions are for administering said compound to an animal having a hyperproliferative disease.
- (Original) The kit of claim 24, wherein said hyperproliferative disease is cancer.